Background

---

Genetic testing (e.g., APOE genotyping) and neuroimaging (e.g., amyloid and tau imaging) are increasingly being used in clinical trials to identify older adults at risk for Alzheimer’s disease. The disclosure of genetic and biomarker information is a requirement of these studies, and many older adults are interested in this type of risk information. Due to their involvement in the REVEAL study and related projects, Dr. Roberts and Professor Uhlmann are assisting several projects outside U-M in developing education and risk communications materials and assessing the psychological and behavioral impacts of risk disclosure.

Research Projects

---

Recently completed project based at the University of Pittsburgh Alzheimer’s Disease Resource Center (J. Lingler, PI) that examines the disclosure of amyloid neuroimaging to individuals with MCI (mild cognitive impairment).

Ongoing project based at the Banner Alzheimer’s Institute (J. Langbaum, PI) assessing APOE and amyloid disclosure to asymptomatic individuals in the context of large AD prevention drug trials.

The Información de la Enfermedad de Alzheimer para Latinos (IDEAL) study, based at Columbia University Alzheimer’s Disease Resource Center (R. Ottman, PI), assessing the impact of APOE disclosure in a cohort of largely Latinx individuals in New York City.

A newly funded project based at Washington University Alzheimer’s Disease Research Center (Mozersky & Hartz, mPIs) where APOE, amyloid, and tau information will be combined to generate risk estimates for disclosure of asymptomatic older adults.

Funding Source

---

All projects listed above are funded by the National Institutes of Health (NIH), primarily through R01 grants from the National Institute of Aging (NIA).

Key Personnel

---

Sample Publications

---

Lingler JH, Sereika SM, Butters MA, Cohen AD, Klunk WE, Knox ML, McDade E, Nadkarnia NK, Roberts JS, Tamres LK, Lopez OL. A Randomized Controlled Trial of Amyloid Positron Emission Tomography Results Disclosure in Mild Cognitive Impairment. Alzheimer’s & Dementia. 16(9). PDF.

Langlois CM, Bradbury A, Wood EM, Roberts JS, Kim S, Reiman EM, Tariot PN, Karlawish J, Langbaum JB. Alzheimer’s Prevention Initiative Generation Program: Development of an APOE Genetic Counseling and Disclosure Process in the Context of Clinical Trials. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2019;5:705-16.

Mattos MK, Sereika SM, Beach SR, Klunk WE, Knox M, Nadkarni N, Parker LS, Roberts JS, Schulz R, Tamres L, Lingler JH. Research use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Imaging. Journal of Alzheimer’s Disease. 2019;71(4):1071-79.

Langbaum JB, Karlawish J, Roberts JS, et al. GeneMatch: A Novel Recruitment Registry to Conduct At-home APOE Genotyping to Enhance Referrals to Alzheimer’s Prevention Studies. Alzheimer’s & Dementia. 2019;15(4):515-24.